Navigation Links
Singulex Advances Conversation on Personalized Medicine
Date:5/13/2008

HALF MOON BAY, Calif., May 13 /PRNewswire/ -- Personalized medicine is changing the face of healthcare. Currently, pharmacogenomic tests can help physicians determine the right dosing schedule for warfarin or to predict the potential for adverse drug reactions. In the near future, health professionals will leverage protein-based biomarkers to predict drug safety and efficacy and to detect disease earlier.

Singulex Inc., a company focused on advancing technologies for early disease detection, today announced that its CEO, Philippe Goix, Ph.D., is chairing a panel on personalized medicine at the Think Tomorrow Today Summit, sponsored by ThinkPanmure. Participants on the panel, entitled "Just for Me: Personalized Medicine," include Michael McKenna, Ph.D., CSO of Tethys Biosciences and Kathryn Phillips, Ph.D., professor of health economics & health services research at UCSF.

"While pharmacogenomics represent much of the current activity in personalized medicine, they are only the tip of the iceberg," said Philippe Goix, CEO of Singulex. "The utility of protein biomarkers could soon eclipse that of pharmacogenomics, allowing much earlier disease detection and also enabling pharmaceutical companies to identify what patient populations will respond to their drug and then to monitor those patients to measure disease regression."

Singulex has pioneered technology that increases the clinical utility of biomarkers using immunoassay technologies. Through collaborations with pharmaceutical and biotechnology companies and academic researchers, the company has shown specifically that the biomarker c Troponin I (cTnI), a validated biomarker for cardiac necrosis, can be detected in healthy people. Singulex can also measure small changes in cTnI levels that indicate stress to the heart, such as during treadmill stress tests, which other technologies cannot do.

About Singulex

Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Alameda, California. To learn more about Singulex, please visit us at http://www.singulex.com.


'/>"/>
SOURCE Singulex Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
2. TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity
3. Imaging Advances Map Brain Areas Affecting Mood
4. Recent Advances Make Sunscreen More Effective and Easier to Use
5. Treatment advances for fibroids, menopause
6. Breast reconstruction advances fix distortions left by lumpectomy
7. Breast Reconstruction Advances Fix Distortions Left by Lumpectomy
8. Minnesota partnership advances potential MS therapy
9. Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DCs National Press Club
10. Latest Advances in Diabetes Research to be Presented in San Francisco, California at Worlds Largest Diabetes Conference, June 6-10, 2008
11. DNV Healthcare Advances in Bid to Accredit Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology: